Objective To analyze the use of proton pump inhibitors( PPIs) in the perioperative period of Zhoushan Hospital,thus to make appropriate management regulations for the clinical application of PPIs. Methods From September 2016 to October 2016,the use of PPIs in 614 surgical patients of Zhoushan Hospital were statistically analyzed. The rationality of the indications,drug use,drug administration,dosage,time,course of treatment,combined medication were analyzed. Results In 614 cases,there were 341 reasonable,unreasonable 273,the failure rate was 44. 46% (273/614). The main manifestations in the non indication of medication and medication course of treatment was too long. Conclusion There are many unreasonable phenomena in the course of clinical use of PPIs. Hospital and clinical pharmacists should strengthen supervision and management of the use of PPIs.

Pluronic modified polyamidoamine (PAMAM) conjugate (PF127-PAMAM) was prepared and the inhibiting effect of MDR against MCF-7/ADR was investigated with doxorubicin (DOX) as model drug. 1H NMR and FTIR spectra showed that the conjugate was synthesized successfully. Element analysis accurately measured that 27.63% amino of per PAMAM was modified by pluronic (PAMAM : PF127, 1 : 35.37 mole ratio). PF127-PAMAM showed an increased size and a reduced zeta potential compared to PAMAM. PF127-PAMAM had lower hemolytic toxicity and cytotoxicity due to the reduced zeta potential and the protection of PF127. Each PF127-PAMAM molecular could load 19.58 DOX molecules, and the complex exhibited sustained and pH-sensitive release behavior. PF127-PAMAM/DOX exhibited weaker cytotoxicity than free DOX in MCF-7 cells; while the complex showed much stronger reverse effect of drug resistance in MCF-7/ADR cells, and resistance reversion index (RRI) was as high as 33.15.